Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE: Latest data burnishes credential of breakthrough cancer diagnostic

Parsortix was better than the existing technology in harvesting head and neck cancer cells, according to work carried out in Greece.
ANGLE: Latest data burnishes credential of breakthrough cancer diagnostic
The company's technology harvests cancer cells from blood

ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) breakthrough cancer diagnostic is better than the existing technology in harvesting head and neck cancer cells, according to work carried out in Greece.

The results of the study by the University of Athens and Attikon University Hospital will be presented at the American Association for Cancer Research conference later. ANGLE calls them “highly encouraging”.

Delegates will hear the Parsortix system was more sensitive and harvested cancer cells circulating in the bloodstream at greater purity than the existing antibody-based approach.

WATCH: ANGLE boss says "customer data validates strategy" ...

A total of 40 patients were trialled using the two approaches. It was also found information on the expression of key genes could be garnered from the Parsortix samples.

This crucial data helps assess the likely response of cancer patients to treatments such as immunotherapies and has the potential to be of “significant clinical importance for the therapy selection and follow-up of patients”, ANGLE said.

"The advantages of the Parsortix system, in head and neck cancer, over the existing antibody-based approaches increases the market opportunity available to ANGLE,” explained the company’s founder Andrew Newland.

“The University of Athens is a leader in CTC [circulating tumour cell] research and the successful completion of this work by a customer validates a key element of our roll-out strategy of using.”

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use